Pengli Li

Cooley advised Core Scientific, a carbon-neutral vertically integrated blockchain infrastructure and mining company, on its merger agreement with special purpose acquisition company (SPAC) Power & Digital Infrastructure Acquisition Corp. The transaction values the combined company, which will be called Core Scientific Inc. and listed on the Nasdaq, at an implied pro forma fully diluted enterprise value of approximately $4.3 billion. Partners Daniel Peale, David Silverman and Nicolas Dumont led the Cooley team advising Core Scientific.

Cooley advised Finch Therapeutics on its $127.5 million initial public offering of 7,500,000 shares of common stock. Finch Therapeutics, whose securities now trade on the Nasdaq Global Select Market under the symbol FNCH, is a clinical-stage microbiome therapeutics company. Partners Div Gupta and Ryan Sansom led the Cooley team.

Cooley advised Anchiano Therapeutics Ltd, a preclinical biopharmaceutical company developing targeted therapies to treat cancer in areas of significant clinical need, on its reverse-merger with Chemomab.

Cooley advised Repare Therapeutics on its $253 million initial public offering of 12,650,000 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Repare Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol “RPTX”, is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Partners Div Gupta, Ryan Sansom and Marc Recht led the Cooley team.

Cooley advised Datadog on its $745.2 million initial public offering of 24,000,000 shares of Class A common stock. Datadog, whose securities now trade on the Nasdaq Global Select Market under the symbol “DDOG,” is a monitoring and analytics platform for developers, IT operations teams and business users in the cloud age. Partners Jodie Bourdet and Nicole Brookshire led the Cooley team.